These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 19501917

  • 1. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.
    Cunningham KA, Carey AJ, Lycke N, Timms P, Beagley KW.
    J Reprod Immunol; 2009 Jul; 81(1):34-8. PubMed ID: 19501917
    [Abstract] [Full Text] [Related]

  • 2. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
    Singh SR, Hulett K, Pillai SR, Dennis VA, Oh MK, Scissum-Gunn K.
    Vaccine; 2006 Feb 20; 24(8):1213-24. PubMed ID: 16194585
    [Abstract] [Full Text] [Related]

  • 3. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK, Aldwell FE, Beagley KW.
    Vaccine; 2009 Oct 19; 27(44):6217-25. PubMed ID: 19698810
    [Abstract] [Full Text] [Related]

  • 4. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA, Stensson A, Schön K, Lycke N.
    Scand J Immunol; 2006 Feb 19; 63(2):97-105. PubMed ID: 16476008
    [Abstract] [Full Text] [Related]

  • 5. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.
    Vaccine; 2011 May 23; 29(23):3951-61. PubMed ID: 21481325
    [Abstract] [Full Text] [Related]

  • 6. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
    Agren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY.
    J Immunol; 1999 Feb 15; 162(4):2432-40. PubMed ID: 9973526
    [Abstract] [Full Text] [Related]

  • 7. Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model.
    Andrew DW, Hafner LM, Beagley KW, Timms P.
    J Reprod Immunol; 2011 Sep 15; 91(1-2):9-16. PubMed ID: 21856018
    [Abstract] [Full Text] [Related]

  • 8. Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate.
    Hickey DK, Jones RC, Bao S, Blake AE, Skelding KA, Berry LJ, Beagley KW.
    Vaccine; 2004 Oct 22; 22(31-32):4306-15. PubMed ID: 15474723
    [Abstract] [Full Text] [Related]

  • 9. Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection.
    Hickey DK, Aldwell FE, Beagley KW.
    Vaccine; 2010 Feb 17; 28(7):1668-72. PubMed ID: 20026449
    [Abstract] [Full Text] [Related]

  • 10. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC, Ekman L, Löwenadler B, Lycke NY.
    J Immunol; 1997 Apr 15; 158(8):3936-46. PubMed ID: 9103464
    [Abstract] [Full Text] [Related]

  • 11. Chlamydia muridarum major outer membrane protein-specific antibodies inhibit in vitro infection but enhance pathology in vivo.
    Cunningham KA, Carey AJ, Hafner L, Timms P, Beagley KW.
    Am J Reprod Immunol; 2011 Feb 15; 65(2):118-26. PubMed ID: 20618179
    [Abstract] [Full Text] [Related]

  • 12. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
    Hadad R, Marks E, Kalbina I, Schön K, Unemo M, Lycke N, Strid Å, Andersson S.
    APMIS; 2016 Dec 15; 124(12):1078-1086. PubMed ID: 27859689
    [Abstract] [Full Text] [Related]

  • 13. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1.
    Xu W, Liu J, Gong W, Chen J, Zhu S, Zhang L.
    Vaccine; 2011 Mar 24; 29(15):2672-8. PubMed ID: 21324344
    [Abstract] [Full Text] [Related]

  • 14. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection.
    Skelding KA, Hickey DK, Horvat JC, Bao S, Roberts KG, Finnie JM, Hansbro PM, Beagley KW.
    Vaccine; 2006 Jan 16; 24(3):355-66. PubMed ID: 16153755
    [Abstract] [Full Text] [Related]

  • 15. Dendritic cells (DCs) transfected with a recombinant adenovirus carrying chlamydial major outer membrane protein antigen elicit protective immune responses against genital tract challenge infection.
    Lü H, Wang H, Zhao HM, Zhao L, Chen Q, Qi M, Liu J, Yu H, Yu XP, Yang X, Zhao WM.
    Biochem Cell Biol; 2010 Aug 16; 88(4):757-65. PubMed ID: 20651849
    [Abstract] [Full Text] [Related]

  • 16. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N.
    Vaccine; 2008 Feb 26; 26(9):1243-52. PubMed ID: 18243429
    [Abstract] [Full Text] [Related]

  • 17. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
    De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W.
    Vaccine; 2006 Jan 30; 24(5):544-51. PubMed ID: 16169634
    [Abstract] [Full Text] [Related]

  • 18. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, Kaastrup P, Lycke N.
    J Immunol; 2001 Sep 15; 167(6):3398-405. PubMed ID: 11544331
    [Abstract] [Full Text] [Related]

  • 19. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
    Lycke N.
    Curr Opin Mol Ther; 2001 Feb 15; 3(1):37-44. PubMed ID: 11249730
    [Abstract] [Full Text] [Related]

  • 20. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model.
    Hansen J, Jensen KT, Follmann F, Agger EM, Theisen M, Andersen P.
    J Infect Dis; 2008 Sep 01; 198(5):758-67. PubMed ID: 18652549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.